1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
WO2013086292A1 - Glucagon formulations - Google Patents
Bydureon, INN-exenatide
Innovative Drug Platform & Formulation Technologies
SPECIAL FEATURE - Injection Devices: Manufacturers Focus on 21st ...
PhactMI BYDUREON® (exenatide extended release)
A Review of the Long-Term Efficacy, Tolerability, and Safety of ...
Dosing with BYDUREON® (exenatide extended-release) injectable ...
Drug Delivery Experts - EuroTIDES 08NOV2017
NEW ZEALAND DATA SHEET 1. PRODUCT NAME 2. QUALITATIVE AND ...
SPECIAL FEATURE - Injection Devices: Manufacturers Focus on 21st ...
Dosing with BYDUREON® (exenatide extended-release) injectable ...
Product Monograph Template - Standard]
Battle of GLP-1 delivery technologies☆ Advanced Drug Delivery Reviews
Exenatide: pharmacokinetics, clinical use, and future directions
Dosing with BYDUREON® (exenatide extended-release) injectable ...
FDA Approves Bydureon BCise – New Autoinjector to Launch Early ...
Formulations and storage conditions for GLP-1 RA products ...
Update on GLP-1 Agonists in Type 2 Diabetes is supported by an ...
AZN - Page 3 of 7
exv99w2
Type 2 Diabetes Treatment | BYDUREON BCise® (exenatide extended ...
Bydureon 2 mg powder and solvent for prolonged-release suspension ...
Select your BYDUREON® (exenatide extended-release) injectable ...
PhactMI BYDUREON® BCise™ (exenatide extended-release)
